Business Update

Pharmaceutical company licenses compound from Millennium Pharmaceuticals

Published in Blood Weekly, September 2nd, 2004

Portola Pharmaceuticals, Inc., announced that it has licensed Millennium Pharmaceuticals, Inc.'s, Factor Xa inhibitor program.

Given orally once a day, the lead compound is a small molecule that acts directly on the blood coagulation enzyme Factor Xa, a clinically validated target involved in the generation of thrombin, the principal mediator of excessive clotting resulting in thrombosis.

Under the terms of the agreement, Portola has licensed exclusive rights to develop, market and commercialize Factor Xa inhibitors worldwide. Portola will make milestone and royalty payments to Millennium upon achievement of certain events.

...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Blood Weekly

Source: Blood Weekly (2004-09-02)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry